<DOC>
	<DOCNO>NCT01043484</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety combination capecitabine + bevacizumab concomitantly radiotherapy versus capecitabine concomitantly radiotherapy , neoadjuvant treatment patient localize resectable rectal cancer .</brief_summary>
	<brief_title>Safety Efficacy Study Compare Capecitabine + Bevacizumab Versus Capecitabine , Concomitantly With Radiotherapy Neoadjuvant Treatment Patients With Localized Resectable Rectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Written inform consent Age ≥18 year ECOG ≤ 1 Histologically confirm carcinoma rectum Localized resectable rectal cancer No metastatic disease Measurable disease Life expectancy 4 month Non prior treatment rectal cancer Adequate haematological function : leu ≥ 4x 109 /l , Hb ≥10 gr/dl , neutropils≥ 1,5 x 109 /l platelet ≥100 x 109 /l Adequate renal function : creatinine ≤ 106 umol/l calculate creatinine clearance &gt; 50 mL/min Adequate liver function : AST , ALT alkaline phosphatase ≤2.5 x UL , bilirubin ≤1.5 x UL Adequate nutritional weight loss &lt; 10 % regular weight albumin ≥ 35 g/l Unresectable rectal cancer Past current history ( within last 5 year prior treatment start ) malignancy . Patients childbearing potential willing use effective mean contraception . Clinically significant cardiovascular disease Lack physical integrity upper gastrointestinal tract , malabsorption syndrome inability take oral medication . Patients subject organ allograft require immunosuppressive treatment . Severe , noncicatrized osseous fracture , wound ulcer . Indications hemorrhagic diathesis coagulopathy . Severe , uncontrolled intercurrent infection severe , uncontrolled concomitant disease . History unexpected severe reaction treatment fluoropyrimidines know deficiency dihydropyrimidine dehydrogenase deficiency ( DPD ) . Patients subject major surgical procedure , open biopsy significant traumatic lesion within 28 day prior begin treatment study foreseen major surgical procedure necessary course study ; fineneedle aspiration within 7 day prior begin treatment study . Current recent use ( within 10 day prior begin treatment study ) oral parenteral anticoagulant complete dos thrombolytic agent . The use low dos warfarin allow , International Normalized Ratio [ INR ] &lt; 1.5 . Daily chronic treatment high dos aspirin ( &gt; 325 mg/day ) nonsteroid antiinflammatory medication ( inhibit platelet function dos use treat chronic inflammatory disease ) . Patients receive drug agent/procedure research , i.e. , participate another clinical trial 4 week prior begin treatment medication study Any psychological , familiar condition suggest patient able complete study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Resectable rectal cancer</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Capecitabine</keyword>
</DOC>